Faeth Therapeutics is pioneering multi-node inhibition of the PAM (PI3K/AKT/mTOR) pathway — the most frequently altered oncogenic pathway in cancer. Our lead candidate PIKTOR is an all-oral combination that is designed to achieve deeper pathway suppression with greater tolerability by targeting multiple nodes simultaneously.
Calendar
–
View all events & presentations
Events and presentations.
Latest
–
View all news
News and updates.
Jun 04 2026
Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON --(BUSINESS WIRE)--Jun. 4, 2026-- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on June 1, 2026, the Compensation Committee of Sensei’s Board of Directors granted three new employees options to purchase an aggregate of 19,300 shares of the Company’s common stock
Read More
May 15 2026
Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
First patient dosed in Phase 1b/2 trial of PIKTOR in HR+/HER2- advanced breast cancer Topline Phase 2 data in patients with advanced endometrial cancer expected in second half 2026 BOSTON --(BUSINESS WIRE)--May 15, 2026-- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today reported financial results
Read More
May 05 2026
Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer
PIKTOR is an investigational all-oral, multi-node inhibitor targeting escape routes in the PI3K/AKT/mTOR pathway that single-node inhibitors leave open BOSTON --(BUSINESS WIRE)--May 5, 2026-- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company, announced today that
Read More
Apr 09 2026
Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
BOSTON --(BUSINESS WIRE)--Apr. 9, 2026-- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that Company management will present at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16 th, 2026 at 12:45 p.m. ET. The live webcast of the presentation may be accessed
Read More
Mar 30 2026
Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
Faeth acquisition adds PIKTOR, an all-oral combination product candidate targeting multiple nodes of the PI3K/AKT/mTOR pathway $200 million private placement supports key clinical milestones in endometrial and breast cancer BOSTON --(BUSINESS WIRE)--Mar. 30, 2026-- Sensei Biotherapeutics, Inc.
Read More